Introduction

A senior U.S. health official faced intense scrutiny after endorsing a major FDA policy change on hormone replacement therapy while holding significant financial stakes in a company that stands to benefit. The case raises serious questions about conflicts of interest at the highest levels of federal health oversight.

What Happened

In late 2025, the Department of Health and Human Services moved to eliminate black box warnings on hormone replacement therapies, aiming to reverse nearly two decades of stigma around menopause treatment. At a press conference, Alicia Jackson, director of the Advanced Research Projects Agency for Health, praised the move, stating it could add up to a decade of healthy years for women. Jackson's endorsement came despite holding at least $115,000 in Evernow, an online platform that connects women with menopause specialists. Ethics experts called the endorsement alarming, noting federal law prohibits government officials from personally and substantially participating in matters affecting their personal finances.

Why This Matters

Jackson founded Evernow before joining ARPA-H, and though she stepped down as CEO, she retained a substantial stock position. Her financial disclosures, filed last October and two months ago, remain uncertified by agency ethics officials. Critics argue that her public support for the policy shift directly benefits her financial interests, especially as Evernow expanded nationally after the policy change. The situation highlights broader concerns about how federal officials navigate financial ties while shaping health policy.

Key Takeaways

  • Jackson endorsed an FDA policy removing black box warnings on hormone replacement therapy.
  • She holds at least $115,000 in Evernow stock, a company profiting from menopause treatments.
  • Ethics experts say the endorsement violates the spirit of federal conflict-of-interest rules.
  • Her financial disclosures remain uncertified, and the agency has not confirmed compliance.
  • The case underscores ongoing gaps in ethics oversight within the current administration.

Conclusion

The controversy surrounding Jackson's policy endorsement and financial ties reveals the tension between federal health leadership and personal financial interests. As ethics experts warn, the situation erodes public trust and highlights the need for stricter enforcement of conflict-of-interest laws. Readers should watch for further developments in Jackson's certification status and any broader reforms to federal ethics protocols.